The estimated Net Worth of Sarah Boyce is at least $11.6 Million dollars as of 6 August 2024. Ms Boyce owns over 28,000 units of Avidity Biosciences stock worth over $9,447,563 and over the last 9 years she sold RNA stock worth over $1,349,420. In addition, she makes $823,093 as Pres and CEO & Director at Avidity Biosciences.
Ms has made over 19 trades of the Avidity Biosciences stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 28,000 units of RNA stock worth $34,720 on 6 August 2024.
The largest trade she's ever made was exercising 300,000 units of Avidity Biosciences stock on 12 June 2024 worth over $372,000. On average, Ms trades about 20,500 units every 80 days since 2016. As of 6 August 2024 she still owns at least 233,043 units of Avidity Biosciences stock.
You can see the complete history of Ms Boyce stock trades at the bottom of the page.
Sarah Boyce is the Pres, CEO & Director at Avidity Biosciences.
As the Pres and CEO & Director of Avidity Biosciences, the total compensation of Ms Boyce at Avidity Biosciences is $823,093. There are no executives at Avidity Biosciences getting paid more.
Ms Boyce is 49, she's been the Pres and CEO & Director of Avidity Biosciences since . There are 6 older and no younger executives at Avidity Biosciences. The oldest executive at Avidity Biosciences, Inc. is Dr. Frank McCormick Ph.D., 71, who is the Scientific Founder & Member of Scientific Advisory Board.
Sarah's mailing address filed with the SEC is C/O AVIDITY BIOSCIENCES, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at Avidity Biosciences have traded over $8,545,325 worth of Avidity Biosciences stock and bought 2,050,000 units worth $36,900,000 . The most active insiders traders include Investments, Lpwong Roderic..., Lilly & Co Eli, and Asset Management, Lp Chen B.... On average, Avidity Biosciences executives and independent directors trade stock every 34 days with the average trade being worth of $3,142,336. The most recent stock trade was executed by Arthur A Levin on 19 August 2024, trading 5,000 units of RNA stock currently worth $6,200.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Avidity Biosciences executives and other stock owners filed with the SEC include: